Trials / Completed
CompletedNCT03822832
A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated
Phase IIa, Multicentre, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Safety, Tolerability and Efficacy of Treatment With BI 655130 in Adult Patients With Moderate to Severe Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this trial is to investigate the safety, tolerability and efficacy of BI 655130 in patients with Atopic Dermatitis (AD) following repeated intravenous administrations compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 655130 | Solution for infusion |
| DRUG | Placebo | Solution for infusion |
Timeline
- Start date
- 2019-02-12
- Primary completion
- 2020-01-17
- Completion
- 2020-07-22
- First posted
- 2019-01-30
- Last updated
- 2025-10-20
- Results posted
- 2022-12-01
Locations
23 sites across 3 countries: United States, Canada, Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03822832. Inclusion in this directory is not an endorsement.